Pindolol use in specific populations: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Use in Specific Populations== | ||
====Pregnancy==== | ====Pregnancy==== |
Revision as of 04:39, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Use in Specific Populations
Pregnancy
Studies in rats and rabbits exceeding 100 times the maximum recommended human doses, revealed no embryotoxicity or teratogenicity. Since there are no adequate and well-controlled studies in pregnant women, and since animal reproduction studies are not always predictive of human response, Visken® (pindolol), as with any drug, should be employed during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers
Since Visken® (pindolol) is secreted in human milk, nursing should not be undertaken by mothers receiving the drug.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.[1]
References
Adapted from the FDA Package Insert.